Inhibition of NADPH oxidase 4 induces apoptosis in malignant mesothelioma: Role of reactive oxygen species

Tanaka,Motoya; Miura,Yuji; Numanami,Hiroki; Karnan,Sivasundaram; Ota,Akinobu; Konishi,Hiroyuki; Hosokawa,Yoshitaka; Hanyuda,Masayuki

doi:10.3892/or.2015.4155

Inhibition of NADPH oxidase 4 induces apoptosis in malignant mesothelioma: Role of reactive oxygen species

Authors:
- Motoya Tanaka
- Yuji Miura
- Hiroki Numanami
- Sivasundaram Karnan
- Akinobu Ota
- Hiroyuki Konishi
- Yoshitaka Hosokawa
- Masayuki Hanyuda
View Affiliations

Affiliations: Department of Thoracic Surgery, Aichi Medical University School of Nursing, Nagakute, Aichi 480-1195, Japan, Pathophysiology, Aichi Medical University School of Nursing, Nagakute, Aichi 480-1195, Japan, Department of Biochemistry, Aichi Medical University School of Medicine, Nagakute, Aichi 480-1195, Japan
Published online on: July 27, 2015 https://doi.org/10.3892/or.2015.4155
Pages: 1726-1732

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive tumor that is characterized by dysregulated growth and resistance to apoptosis. Reactive oxygen species (ROS)-generating NADPH oxidase (Nox) family enzymes have been suggested to be involved in neoplastic proliferation. Both the antioxidant N-acetylcysteine (NAC) and the inhibitor of flavoprotein-dependent oxidase, diphenylene iodonium (DPI), inhibited the cell viability of MPM cells in a dose-dependent manner. To examine whether Nox-mediated ROS generation confers antiapoptotic activity and thus a growth advantage to MPM cells, we analyzed the mRNA expression of Nox family members using quantitative RT-PCR in 7 MPM cell lines and a normal mesothelial cell line. Nox4 mRNA was expressed in all of the examined MPM cell lines, whereas little or no Nox2, Nox3 and Nox5 mRNA expression was detected. In 2 MPM cell lines, Nox4 mRNA expression was significantly higher than that in a normal mesothelial cell line. siRNAs targeting Nox4 suppressed ROS generation and cell viability in the MPM cell lines. In addition, DPI treatment and knockdown of Nox4 attenuated phosphorylation of AKT and ERK. Taken together, our results indicate that Nox4-mediated ROS, at least in part, transmit cell survival signals and their depletion leads to apoptosis, thus highlighting the Nox4-ROS-AKT signaling pathway as a potential therapeutic target for MPM treatment.

View Figures

View References

1	Robinson BW and Lake RA: Advances in malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005. View Article : Google Scholar : PubMed/NCBI
2	Campbell NP and Kindler HL: Update on malignant pleural mesothelioma. Semin Respir Crit Care Med. 32:102–110. 2011. View Article : Google Scholar : PubMed/NCBI
3	Peto J, Decarli A, La Vecchia C, Levi F and Negri E: The European mesothelioma epidemic. Br J Cancer. 79:666–672. 1999. View Article : Google Scholar : PubMed/NCBI
4	Murayama T: Epidemic of asbestos related diseases. Proceedings of the global Asbestos Congress (Tokyo); pp. 172004
5	Stewart DJ, Martin-Ucar A, Pilling JE, Edwards JG, O'Byrne KJ and Waller DA: The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. Ann Thorac Surg. 78:245–252. 2004. View Article : Google Scholar : PubMed/NCBI
6	Takahashi K: Emerging health effects of asbestos in Asia. Proceedings of the Global Asbestos Congress (Tokyo); pp. 22004
7	Murayama T, Takahashi K, Natori Y and Kurumatani N: Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med. 49:1–7. 2006. View Article : Google Scholar
8	Rascoe PA, Jupiter D, Cao X, Littlejohn JE and Smythe WR: Molecular pathogenesis of malignant mesothelioma. Expert Rev Mol Med. 14:e122012. View Article : Google Scholar : PubMed/NCBI
9	Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y, et al: LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 71:873–883. 2011. View Article : Google Scholar : PubMed/NCBI
10	Fujii M, Toyoda T, Nakanishi H, Yatabe Y, Sato A, Matsudaira Y, Ito H, Murakami H, Kondo Y, Kondo E, et al: TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med. 209:479–494. 2012. View Article : Google Scholar : PubMed/NCBI
11	Shi Y, Moura U, Opitz I, Soltermann A, Rehrauer H, Thies S, Weder W, Stahel RA and Felley-Bosco E: Role of hedgehog signaling in malignant pleural mesothelioma. Clin Cancer Res. 18:4646–4656. 2012. View Article : Google Scholar : PubMed/NCBI
12	Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, et al: Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 43:1022–1025. 2011. View Article : Google Scholar : PubMed/NCBI
13	Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, Seepo S, Meyerson M and Pass HI: Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 75:264–269. 2015. View Article : Google Scholar
14	Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
15	Tsao AS, Wistuba I, Roth JA and Kindler HL: Malignant pleural mesothelioma. J Clin Oncol. 27:2081–2090. 2009. View Article : Google Scholar : PubMed/NCBI
16	Stahel RA and Weder W: Improving the outcome in malignant pleural mesothelioma: Nonaggressive or aggressive approach? Curr Opin Oncol. 21:124–130. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, et al: Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 30:2509–2515. 2012. View Article : Google Scholar : PubMed/NCBI
18	Brar SS, Kennedy TP, Sturrock AB, Huecksteadt TP, Quinn MT, Whorton AR and Hoidal JR: An NAD(P)H oxidase regulates growth and transcription in melanoma cells. Am J Physiol Cell Physiol. 282:C1212–C1224. 2002. View Article : Google Scholar : PubMed/NCBI
19	Lambeth JD: NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol. 4:181–189. 2004. View Article : Google Scholar : PubMed/NCBI
20	Dworakowski R, Anilkumar N, Zhang M and Shah AM: Redox signalling involving NADPH oxidase-derived reactive oxygen species. Biochem Soc Trans. 34:960–964. 2006. View Article : Google Scholar : PubMed/NCBI
21	Chen K, Craige SE and Keaney JF Jr: Downstream targets and intracellular compartmentalization in Nox signaling. Antioxid Redox Signal. 11:2467–2480. 2009. View Article : Google Scholar : PubMed/NCBI
22	Storz P: Reactive oxygen species in tumor progression. Front Biosci. 10:1881–1896. 2005. View Article : Google Scholar : PubMed/NCBI
23	Szatrowski TP and Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51:794–798. 1991.PubMed/NCBI
24	Mochizuki T, Furuta S, Mitsushita J, Shang WH, Ito M, Yokoo Y, Yamaura M, Ishizone S, Nakayama J, Konagai A, et al: Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene. 25:3699–3707. 2006. View Article : Google Scholar : PubMed/NCBI
25	Vaquero EC, Edderkaoui M, Pandol SJ, Gukovsky I and Gukovskaya AS: Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem. 279:34643–34654. 2004. View Article : Google Scholar : PubMed/NCBI
26	Cheng G, Cao Z, Xu X, van Meir EG and Lambeth JD: Homologs of gp91phox: Cloning and tissue expression of Nox3, Nox4, and Nox5. Gene. 269:131–140. 2001. View Article : Google Scholar : PubMed/NCBI
27	Donkó A, Péterfi Z, Sum A, Leto T and Geiszt M: Dual oxidases. Philos Trans R Soc Lond B Biol Sci. 360:2301–2308. 2005. View Article : Google Scholar : PubMed/NCBI
28	Geiszt M, Witta J, Baffi J, Lekstrom K and Leto TL: Dual oxidases represent novel hydrogen peroxide sources supporting mucosal surface host defense. FASEB J. 17:1502–1504. 2003.PubMed/NCBI
29	Juhasz A, Ge Y, Markel S, Chiu A, Matsumoto L, van Balgooy J, Roy K and Doroshow JH: Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues. Free Radic Res. 43:523–532. 2009. View Article : Google Scholar : PubMed/NCBI
30	Wu Y, Antony S, Juhasz A, Lu J, Ge Y, Jiang G, Roy K and Doroshow JH: Up-regulation and sustained activation of Stat1 are essential for interferon-gamma (IFN-gamma)-induced dual oxidase 2 (Duox2) and dual oxidase A2 (DuoxA2) expression in human pancreatic cancer cell lines. J Biol Chem. 286:12245–12256. 2011. View Article : Google Scholar : PubMed/NCBI
31	Doroshow JH, Juhasz A, Ge Y, Holbeck S, Lu J, Antony S, Wu Y, Jiang G and Roy K: Antiproliferative mechanisms of action of the flavin dehydrogenase inhibitors diphenylene iodonium and di-2-thienyliodonium based on molecular profiling of the NCI-60 human tumor cell panel. Biochem Pharmacol. 83:1195–1207. 2012. View Article : Google Scholar : PubMed/NCBI
32	Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, Matsui WH, Arai S, Fuchs EJ, Vogelsang GB, et al: Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood. 104:2187–2193. 2004. View Article : Google Scholar : PubMed/NCBI
33	Lee YJ, Cho HN, Soh JW, Jhon GJ, Cho CK, Chung HY, Bae S, Lee SJ and Lee YS: Oxidative stress-induced apoptosis is mediated by ERK1/2 phosphorylation. Exp Cell Res. 291:251–266. 2003. View Article : Google Scholar : PubMed/NCBI
34	Carbone M and Yang H: Molecular pathways: Targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res. 18:598–604. 2012. View Article : Google Scholar :
35	Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, Gazdar AF, Pass HI and Yang H: Malignant mesothelioma: Facts, myths, and hypotheses. J Cell Physiol. 227:44–58. 2012. View Article : Google Scholar
36	Ushio-Fukai M and Nakamura Y: Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett. 266:37–52. 2008. View Article : Google Scholar : PubMed/NCBI
37	Shono T, Yokoyama N, Uesaka T, Kuroda J, Takeya R, Yamasaki T, Amano T, Mizoguchi M, Suzuki SO, Niiro H, et al: Enhanced expression of NADPH oxidase Nox4 in human gliomas and its roles in cell proliferation and survival. Int J Cancer. 123:787–792. 2008. View Article : Google Scholar : PubMed/NCBI
38	Yamaura M, Mitsushita J, Furuta S, Kiniwa Y, Ashida A, Goto Y, Shang WH, Kubodera M, Kato M, Takata M, et al: NADPH oxidase 4 contributes to transformation phenotype of melanoma cells by regulating G2-M cell cycle progression. Cancer Res. 69:2647–2654. 2009. View Article : Google Scholar : PubMed/NCBI
39	Graham KA, Kulawiec M, Owens KM, Li X, Desouki MM, Chandra D and Singh KK: NADPH oxidase 4 is an oncoprotein localized to mitochondria. Cancer Biol Ther. 10:223–231. 2010. View Article : Google Scholar : PubMed/NCBI
40	Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, Kondo Y, Osada H, Shimokata K, Horio Y, et al: Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep. 2:181–188. 2009.PubMed/NCBI
41	Cole GW Jr, Alleva AM, Zuo JT, Sehgal SS, Yeow WS, Schrump DS and Nguyen DM: Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126. Anticancer Res. 26A:809–821. 2006.